Gandeeva Therapeutics

Based in Canada, Gandeeva Therapeutics develops precision medicines by leveraging AI/machine learning, structural biology, biochemistry, and imaging technologies. It follows the cryogenic electron microscopy (cryo-EM) approach that captures detailed images of proteins to determine their structures to the level as small as two angstroms (one-tenth of a nanometer) and zoom in on specific areas of a protein, thereby providing insights to accelerate the drug discovery process. This approach is reportedly simpler and less time-consuming compared to its counterpart X-ray crystallography, which involves crystals packed with proteins that are shot by x-rays, to determine the structures of proteins.

As of March 2024, the company had four drug candidates in the discovery stage.

Key customers and partnerships

In March 2023 , Gandeeva Therapeutics partnered with Moderna to explore how Gandeeva’s technology platform can be utilized in one of Moderna’s programs.

Funding and financials

Gandeeva Therapeutics emerged from stealth with a USD 40 million Series A funding round in January 2022 , which involved investments from Leaps by Bayer AG (Bayer’s impact investment arm) and Amgen Ventures (Amgen venture capital fund). Other investors including Obvious Ventures and Amgen Ventures also participated in the round. The funds were expected to advance the company’s cryo-EM platform.